| Sunday January 28, 2018 |
| 17:00 | Opening Remarks |
|
| 17:15 | Title to be announced |
Erick M. CARREIRA
(ETH ZÜRICH, Zürich, Switzerland) |
| 18:15 | Poster Session |
|
| 20:15 | End of Day 1 |
|
| Monday January 29, 2018 |
| Session 1: Advances in Synthetic Methods
|
|
| Session Chair |
Nuno MAULIDE
(UNIVERSITY OF VIENNA, Vienna, Austria) |
| 08:30 | Assembly Line Synthesis |
Varinder K. AGGARWAL
(UNIVERSITY OF BRISTOL, Bristol, United Kingdom) |
| 09:00 | Photochemical Reactions en route to Structurally Complex Molecules |
Thorsten BACH
(TECHNISCHE UNIVERSITÄT MÜNCHEN, Garching, Germany) |
| 09:30 | Coffee Break |
|
| 10:00 | Small Ring Chemistry |
Ilan MAREK
(ISRAEL INSTITUTE OF TECHNOLOGY, Haifa, Israel) |
| 10:30 | Open Slot for an Oral Communication selected from submitted Abstracts |
|
| Session 2: Addressing Preclinical Toxicity – Approaches and Lessons Learned
|
|
| Session Chair |
Andy PEAT
(GLAXOSMITHKLINE, United States) |
| 17:30 | Mechanism-Based Toxicities Associated With NAMPT Inhibition and Related Mitigation Strategies |
Peter DRAGOVICH
(GENENTECH INC., San Francisco, United States) |
| 18:00 | Utilizing in Depth Understanding of a Molecules Off Target Profile to Tailor Clinical and Preclinical Safety Assessments |
Douglas THOMSON
(CELLZOME GMBH, Heidelberg, Germany) |
| 18:30 | Coffee Break |
|
| 19:00 | Overcoming Drug Bioactivation in Lead Optimization: Case Studies |
Axel PÄHLER
(F. HOFFMANN-LA ROCHE, Basel, Switzerland) |
| 19:30 | Open Slot for an Oral Communication selected from submitted Abstracts |
|
| 20:00 | Panel Discussion |
|
| 20:45 | End of Day 2 |
|
| Tuesday January 30, 2018 |
| Session 3: Advances in Lead Generation
|
|
| Session Chair |
Doris RIETHER
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach an der Riss, Germany) |
| 08:30 | ADAS (Affinity Directed Automated Synthesis): A New Technology to Accelerate Lead Generation |
Eva María MARTÍN
(ELI LILLY, Madrid, Spain) |
| 09:00 | A Chemist’s Guide to Modern Phenotypic Drug Discovery |
Monika ERMANN
(EVOTEC LTD, Oxfordshire, United Kingdom) |
| 09:30 | Coffee Break |
|
| 10:00 | Open Slot for an Oral Communication selected from submitted Abstracts |
|
| 10:30 | From Multiple Hit Series to (Pre)Clinical Candidates Using DNA Encoded Library Technology |
Sanne SCHRØDER GLAD
(NUEVOLUTION A/S, Copenhagen, Denmark) |
| Session 4: Chemical Biology in Drug and Target Discovery
|
|
| Session Chair |
Matthew HAYWARD
(PFIZER, Groton, United States) |
| 17:30 | Biosensors for Measuring Metabolite and Drug Concentrations in Living Cells |
Kai JOHNSSON
(SWISS FEDERAL INSTITUTE OF TECHNOLOGY IN LAUSANNE (EPFL), Lausanne, Switzerland) |
| 18:00 | Open Slot for an Oral Communication selected from submitted Abstracts |
|
| 18:30 | Coffee Break |
|
| 19:00 | Activity-based proteomics – Protein and Ligand Discovery on a Global Scale |
Benjamin CRAVATT
(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States) |
| 20:00 | End of Day 3 |
|
| Wednesday January 31, 2018 |
| Session 5: Alternative Modalities
|
|
| Session Chair |
Philippe NANTERMET
(MERCK, SHARP & DOHME, West Point, United States) |
| 08:30 | Discovery Chemistry Modalities: Chemistry on the Macromolecular Scale |
David TELLERS
(MERCK & CO. INC (MSD), West Point, United States) |
| 09:00 | New Modalities for Challenging Targets in Drug Discovery |
Eric VALEUR
(ASTRAZENECA R&D GOTHENBURG, Mölndal, Sweden) |
| 09:30 | Coffee Break |
|
| 10:00 | Messenger RNA as A Novel Therapeutic Approach |
Matthew STANTON
(MODERNA THERAPEUTICS, Cambridge, United States) |
| 10:30 | Open Slot for an Oral Communication selected from submitted Abstracts |
|
| Session 6: Late Stage Functionalization
|
|
| Session Chair |
Guido KOCH
(NOVARTIS PHARMA AG, Basel, Switzerland) |
| 17:30 | Title to be announced |
Matthew GAUNT
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom) |
| 18:00 | Title to be announced |
Nicolai CRAMER
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE, Lausanne, Switzerland) |
| 18:30 | Coffee Break |
|
| 19:00 | Catalytic Approaches to Simplifying Synthesis |
Darren J. DIXON
(UNIVERSITY OF OXFORD, Oxford, United Kingdom) |
| 19:30 | Open Slot for an Oral Communication selected from submitted Abstracts |
|
| 20:00 | End of the Scientific Programme on Day 4 |
|
| 21:00 | Conference Dinner |
|
| 23:00 | End of Day 4 |
|
| Thursday February 1, 2018 |
| Session 7: Challenges and Opportunities in Fragment Based Drug Discovery
|
|
| Session Chair |
Alison WOOLFORD
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom) |
| 08:30 | Drug Discovery for Challenging Targets by X-ray Crystallographic Fragment Screening |
Tom HEIGHTMAN
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom) |
| 09:00 | The Impact of Fragments on Drug Discovery |
Rod HUBBARD
(UNIVERSITY OF YORK & VERNALIS, Cambridge, United Kingdom) |
| 09:30 | Coffee Break |
|
| 10:00 | Title to be announced |
Mairi SIME
(BEATSON INSTITUTE FOR CANCER RESEARCH, Bearsden Glasgow , United Kingdom) |
| 10:30 | Open Slot for an Oral Communication selected from submitted Abstracts |
|
| Session 8: Drug Discovery Tales
|
|
| Session Chair |
Sarah SKERRATT
(VERTEX PHARMACEUTICALS, Oxon, United Kingdom) |
| 17:30 | Open Slot for an Oral Communication selected from submitted Abstracts |
|
| 17:50 | Open Slot for an Oral Communication selected from submitted Abstracts |
|
| 18:10 | Open Slot for an Oral Communication selected from submitted Abstracts |
|
| 18:30 | Coffee Break |
|
| 19:00 | Title to be announced |
Anabella VILLALOBOS
(BIOGEN, Cambridge, United States) |
| 19:45 | Closing Remarks |
|
| 20:00 | End of Symposium |
|
